Cizzle Bio Launches Cancer Blood Tests in the Cayman Islands

Press Release
Written By Cizzle Bio, Inc.
Exterior view of Doctors Hospital in the Cayman Islands, featuring a roundabout garden and fountain—site of Cizzle Bio’s international launch of lung and gastric cancer blood tests.

Cizzle Bio has partnered with Doctors Hospital in the Cayman Islands to offer its CIZ1B lung cancer and DEX-G2 gastric cancer biomarker blood tests. This milestone expands access to earlier and more accurate detection for two of the world’s deadliest cancers.

The agreement supports Cizzle Bio’s mission to make early cancer detection more accessible in both international and U.S. markets.

Read the full press release here.

Learn more at www.cizzlebio.com

Cizzle Bio, Inc.

Cizzle Bio, Inc. is a pioneering biotechnology company focused on developing innovative solutions for early lung cancer detection. With a commitment to advancing cancer diagnostics, Cizzle Bio, Inc. collaborates with leading research institutions and healthcare professionals to bring groundbreaking biomarker blood tests to market, aiming to improve patient outcomes and save lives.

https://www.cizzlebio.com
Next

ASCO Study Abstract Shows Cizzle Bio’s CIZ1B Biomarker Test for Lung CancerCould Save $518M in Annual Medicare Costs